Casak SJ, Marcus L, Fashoyin-Aje L, Mushti SL, et al. FDA Approval Summary: Pembrolizumab for the First-line Treatment of Patients with MSI-H/dMMR Advanced Unresectable or Metastatic Colorectal Carcinoma. Clin Cancer Res 2021;27:4680-4684.
PMID: 33846198